Antibody-mediated retinal pericyte injury: Implications for diabetic retinopathy

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 9, 2012, Pages 5520-5526

  Li, Yan ^a   Smith, Dawn ^a   Li, Qing ^a   Sheibani, Nader ^b   Huang, Suber ^a   Kern, Timothy ^a   Nagaraj, Ram H ^a   Lin, Feng ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; CD38 ANTIGEN; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA; COMPLEMENT; IMMUNOGLOBULIN G;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DAMAGE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY TEST; DIABETIC RETINOPATHY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; MOUSE; NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; ADULT; AGED; ANIMAL; C57BL MOUSE; CELL CULTURE; HYPERGLYCEMIA; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; PATHOLOGY; PHYSIOLOGY; RETINA BLOOD VESSEL; SERUM;

ADULT; AGED; ANIMALS; ANTIGENS, CD38; AUTOANTIBODIES; AUTOANTIGENS; CELLS, CULTURED; COMPLEMENT SYSTEM PROTEINS; DIABETIC RETINOPATHY; HUMANS; HYPERGLYCEMIA; IMMUNE TOLERANCE; IMMUNOGLOBULIN G; MICE; MICE, INBRED C57BL; PERICYTES; RETINAL VESSELS; SERUM;

EID: 84867911383     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-10010     Document Type: Article

References (30)

1. Sims DE. The pericyte-a review. Tissue Cell. 1986;18:153-174.
2. Darland DC, Massingham LJ, Smith SR, Piek E, Saint-Geniez M, D'Amore PA. Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival. Dev Biol. 2003;264:275-288.
3. Antonelli-Orlidge A, Saunders KB, Smith SR, D'Amore PA. An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sci U S A. 1989;86:4544-4548.
4. Yafai Y, Iandiev I, Wiedemann P, Reichenbach A, Eichler W. Retinal endothelial angiogenic activity: effects of hypoxia and glial (Muller) cells. Microcirculation. 2004;11:577-586.
5. Liu B, Bhat M, Padival AK, Smith DG, Nagaraj RH. Effect of dicarbonyl modification of fibronectin on retinal capillary pericytes. Invest Ophthalmol Vis Sci. 2004;45:1983-1995.
6. Denis U, Lecomte M, Paget C, Ruggiero D, Wiernsperger N, Lagarde M. Advanced glycation end-products induce apoptosis of bovine retinal pericytes in culture: involvement of diacylglycerol/ceramide production and oxidative stress induction. Free Radic Biol Med. 2002;33:236-247.
7. Pomero F, Allione A, Beltramo E, et al. Effects of protein kinase C inhibition and activation on proliferation and apoptosis of bovine retinal pericytes. Diabetologia. 2003;46:416-419.
8. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11:785-797.
9. Daha NA, Banda NK, Roos A, et al. Complement activation by (auto-) antibodies. Mol Immunol. 2011;48:1656-1665.
10. Miller AG, Smith DG, Bhat M, Nagaraj RH. Glyoxalase I is critical for human retinal capillary pericyte survival under hyperglycemic conditions. J Biol Chem. 2006;281:11864-11871.
11. Scheef EA, Sorenson CM, Sheibani N. Attenuation of proliferation and migration of retinal pericytes in the absence of thrombospondin-1. Am J Physiol Cell Physiol. 2009;296: C724-734.
12. Quigg RJ, Holers VM, Morgan BP, Sneed AE 3rd. Crry and CD59 regulate complement in rat glomerular epithelial cells and are inhibited by the nephritogenic antibody of passive Heymann nephritis. J Immunol. 1995;154:3437-3443.
13. Quigg RJ, Nicholson-Weller A, Cybulsky AV, Badalamenti J, Salant DJ. Decay accelerating factor regulates complement activation on glomerular epithelial cells. J Immunol. 1989; 142:877-882.
14. Tu Z, Li Y, Smith DS, et al. Retinal pericytes inhibit activated T cell proliferation. Invest Ophthalmol Vis Sci. 2011;52:9005-9010.
15. Kern TS, Tang J, Berkowitz BA. Validation of structural and functional lesions of diabetic retinopathy in mice. Mol Vis. 2010;16:2121-2131.
16. Mallone R, Perin PC. Anti-CD38 autoantibodies in type? diabetes. Diabetes Metab Res Rev. 2006;22:284-294.
17. Limb GA, Chignell AH, Green W, LeRoy F, Dumonde DC. Distribution of TNF alpha and its reactive vascular adhesion molecules in fibrovascular membranes of proliferative diabetic retinopathy. Br J Ophthalmol. 1996;80:168-173.
18. Limb GA, Soomro H, Janikoun S, Hollifield RD, Shilling J. Evidence for control of tumour necrosis factor-alpha (TNFalpha) activity by TNF receptors in patients with proliferative diabetic retinopathy. Clin Exp Immunol. 1999;115:409-414.
19. Johnsen-Soriano S, Sancho-Tello M, Arnal E, et al. IL-2 and IFNgamma in the retina of diabetic rats. Graefes Arch Clin Exp Ophthalmol. 2010;248:985-990.
20. Attawia MA, Nayak RC. Circulating antipericyte autoantibodies in diabetic retinopathy. Retina. 1999;19:390-400.
21. Nayak RC, Agardh CD, Kwok MG, Stjernquist H, Farthing-Nayak PJ, Agardh E. Circulating anti-pericyte autoantibodies are present in Type 2 diabetic patients and are associated with non-proliferative retinopathy. Diabetologia. 2003;46:511-513.
22. Terhorst C, van Agthoven A, LeClair K, Snow P, Reinherz E, Schlossman S. Biochemical studies of the human thymocyte cell-surface antigens T6, T9 and T10. Cell. 1981;23:771-780.
23. Jackson DG, Bell JI. Isolation of a cDNA encoding the human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiation. J Immunol. 1990;144:2811-2815.
24. Ikehata F, Satoh J, Nata K, et al. Autoantibodies against CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) that impair glucose-induced insulin secretion in noninsulin-dependent diabetes patients. J Clin Invest. 1998;102:395-401.
25. Pupilli C, Giannini S, Marchetti P, et al. Autoantibodies to CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) in Caucasian patients with diabetes: effects on insulin release from human islets. Diabetes. 1999;48:2309-2315.
26. Mallone R, Ortolan E, Baj G, et al. Autoantibody response to CD38 in Caucasian patients with type 1 and type 2 diabetes: immunological and genetic characterization. Diabetes. 2001; 50:752-762.
27. Mallone R, Ortolan E, Pinach S, et al. Anti-CD38 autoantibodies: characterisation in new-onset type I diabetes and latent autoimmune diabetes of the adult (LADA) and comparison with other islet autoantibodies. Diabetologia. 2002;45:1667-1677.
28. Lin F, Kaminski HJ, Conti-Fine BM, Wang W, Richmonds C, Medof ME. Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decayaccelerating factor protection. J Clin Invest. 2002;110:1269-1274.
29. Molina H. The murine complement regulator Crry: new insights into the immunobiology of complement regulation. Cell Mol Life Sci. 2002;59:220-229.
30. Zhang J, Gerhardinger C, Lorenzi M. Early complement activation and decreased levels of glycosylphosphatidylinositol-anchored complement inhibitors in human and experimental diabetic retinopathy. Diabetes. 2002;51:3499-3504.